Acadia Pharmaceuticals Inc. (ACAD), Thursday announced results from LILAC-1 and LILAC-2 studies, showing improvement in patients with rett syndrome, which was measured by the Rett Syndrome Behaviour Questionnaire.
Rett syndrome is a rare, complex, neurodevelopmental disorder, causing symptoms such as development of unusual hand movements, mobility issues, and gait abnormalities.
LILAC-1 evaluated the long-term safety and efficacy of Daybue in patients with rett syndrome five to 21 years of age, whereas LILAC-2 evaluated the long-term safety and efficacy of Daybue in females aged five to 22 years who completed LILAC-1, the company stated.
The results, published in the journal Med, revealed that Daybue's safety profile was consistent with results from the LAVENDER trial. However, common side effects such as diarrhea and vomiting were reported during the studies.
Currently, Acadia's stock is moving down 1.25 percent, to $18.12 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.